Clinical Trials Logo

Advanced Solid Tumor clinical trials

View clinical trials related to Advanced Solid Tumor.

Filter by:

NCT ID: NCT05525559 Not yet recruiting - Clinical trials for Advanced Solid Tumor

SHP2 Inhibitor ET0038 Monotherapy in Patients With Advanced Solid Tumors

FIRST
Start date: November 1, 2022
Phase: Phase 1
Study type: Interventional

This is a Phase I, open-label, multi-center, dose-finding study to assess the safety, pharmacokinetics, and preliminary efficacy of ET0038 in patients with advanced solid tumors. It is anticipated that approximately 34 subjects will be enrolled in the dose-escalation phase of the study. ET0038 will be administered orally once daily (QD) in 21-day treatment cycles.

NCT ID: NCT05515185 Not yet recruiting - Clinical trials for Advanced Solid Tumor

B7-H3 Targeting CAR-T Cells Therapy for B7-H3 Positive Solid Tumors

Start date: September 9, 2022
Phase: Early Phase 1
Study type: Interventional

This is a clinical study to evaluate the safety and efficacy of CAR-T cells in the treatment of patients with advanced solid tumors in China.

NCT ID: NCT05478486 Not yet recruiting - Clinical trials for Advanced Solid Tumor

Assessment of Safety, Tolerability and PK Profile of MSP008-22 in Patients With Advanced Solid Tumours

Start date: September 1, 2022
Phase: Phase 1
Study type: Interventional

This is the 'first-in-human' clinical trial of the Investigational Medicinal Product (IMP), Tablet formulation for Oral dosing of MSP008-22, a molecule (new chemical entity) with anticancer properties.

NCT ID: NCT05474859 Not yet recruiting - Clinical trials for Advanced Solid Tumor

Subjects With Advanced or Metastatic Solid Tumor Malignancies

Start date: March 2024
Phase: Phase 1
Study type: Interventional

This study is an open-label, Phase 1, multicenter, continuous dose escalation study of XT-0528 in adult subjects with Advanced or Metastatic Solid Tumor Malignancies. The study will consist of 4 periods: Screening Period (up to 28 days prior to Cycle 1 Day 1) Safety Run-in Period (Cycle 1; continuous dosing on Days 1-21 of 28-day cycle) Continuous Dosing Period (Cycle 2 and beyond; continuous dosing on Days 1-28 of 28-day cycle) Safety Follow-up Period (30 days post-last dose).

NCT ID: NCT05429398 Not yet recruiting - Clinical trials for Advanced Solid Tumor

A Study of Linperlisib Combination With Camrelizumab in Patients With Solid Tumor

Start date: June 30, 2022
Phase: Phase 1
Study type: Interventional

It is a single-arm, open-label, multicenter, phase I trial,aiming at exploring the MTD and RP2D of Linperlisib combination with Camrelizumab in treating patients with advanced solid tumor,observing the preliminary efficacy.

NCT ID: NCT05344742 Not yet recruiting - Clinical trials for Advanced Solid Tumor

A Study of Mitoxantrone Hydrochloride Liposome Injection Combination Therapy in Chinese Patients With Advanced Solid Tumors

Start date: April 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the tolerability, safety, pharmacokinetics (PK) and efficacy of mitoxantrone hydrochloride liposome injection combination therapy in Chinese patients with advanced solid tumors.

NCT ID: NCT05341557 Not yet recruiting - Lymphoma Clinical Trials

A Phase 1 Study of BPI-371153 in Subjects With Advanced Solid Tumors or Relapsed/Refractory Lymphoma

Start date: June 2022
Phase: Phase 1
Study type: Interventional

A first-in-human study to evaluate the safety, tolerability and maximum tolerated dose (MTD) and establish the recommended phase 2 dose (RP2D) of BPI-371153, a PD-L1 Inhibitor, in patients with advanced solid tumors or relapsed/refractory lymphoma.

NCT ID: NCT05320874 Not yet recruiting - Clinical trials for Advanced Solid Tumor

A Study of KM257 in Patients With Advanced HER2-positive or Expressing Solid Tumors.

Start date: April 2022
Phase: Phase 1
Study type: Interventional

This is a first-in-human, 2-part study to investigate the safety, tolerability, pharmacokinetics and efficacy of KM257 by itself and combined with selected chemotherapy agents in patients with advanced HER2-positive or expressing cancers.

NCT ID: NCT05258266 Not yet recruiting - Clinical trials for Advanced Solid Tumor

A Study to Evaluate the Activity, Safety and Tolerability of ZX-101A in Advanced Solid Tumors

Start date: March 9, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

ZX-101A-201 is a phase I, open-label, multicenter study which includes dose escalation and dose expansion of ZX-101A. It is designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and antitumor activity of ZX-101A in patients with advanced solid tumors.

NCT ID: NCT05058352 Not yet recruiting - Clinical trials for Advanced Solid Tumor

A Study of HS269 in Patients With Advanced Solid Tumors

Start date: October 2021
Phase: Phase 1
Study type: Interventional

This is a Phase I, open-label, first in human study of HS269 tablet, a small molecule highly-selective RET Inhibitor. The dose-escalation study will assess the safety, tolerability, and pharmacokinetics of HS269 and determine the dose and schedule to be used in Phase II. Seventeen to thirty-six patients with advanced solid tumor may be enrolled in this study.